Search research articles
Contact Us
Filters
Showing results (1-10 of 203) with videos related to
Page
of 21
Sort By:
Statistics in Medicine
|
January 6, 2023
Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy
Hajime Uno, Miki Horiguchi
JCO Precision Oncology
|
July 22, 2024
Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis
Hajime Uno, Miki Horiguchi
Statistics in Medicine
|
May 21, 2020
On permutation tests for comparing restricted mean survival time with small sample from randomized trials
Miki Horiguchi, Hajime Uno
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2020
Is the Log-Rank and Hazard Ratio Test/Estimation the Best Approach for Primary Analysis for All Trials?
Hajime Uno, Lu Tian
Biometrical Journal. Biometrische Zeitschrift
|
March 24, 2025
On Sample Size Determination for Augmented Tests Based on Restricted Mean Survival Time in Randomized Clinical Trials
Satoshi Hattori, Hajime Uno
Familial Cancer
|
January 31, 2018
Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers
Fay Kastrinos, Hajime Uno, Sapna Syngal
Contemporary Clinical Trials Communications
|
April 27, 2018
Decision on performing interim analysis for comparative clinical trials
Kyongsun Pak, Susanna Jacobus, Hajime Uno
Biostatistics (Oxford, England)
|
December 24, 2025
While-alive regression analysis of composite survival endpoints
Xi Fang, Hajime Uno, Fan Li
Statistics in Medicine
|
January 19, 2023
On assessing survival benefit of immunotherapy using long-term restricted mean survival time
Miki Horiguchi, Lu Tian, Hajime Uno
BMC Public Health
|
June 30, 2010
Clinical consequences of road traffic injuries among the elderly in Japan
Takashi Nagata, Hajime Uno, Melissa J Perry
Page
of 21
Search research articles
Search
Showing results (1-10 of 203) with videos related to
Sort By:
Page
of 21
Statistics in Medicine
|
January 6, 2023
Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy
Hajime Uno, Miki Horiguchi
JCO Precision Oncology
|
July 22, 2024
Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis
Hajime Uno, Miki Horiguchi
Statistics in Medicine
|
May 21, 2020
On permutation tests for comparing restricted mean survival time with small sample from randomized trials
Miki Horiguchi, Hajime Uno
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2020
Is the Log-Rank and Hazard Ratio Test/Estimation the Best Approach for Primary Analysis for All Trials?
Hajime Uno, Lu Tian
Biometrical Journal. Biometrische Zeitschrift
|
March 24, 2025
On Sample Size Determination for Augmented Tests Based on Restricted Mean Survival Time in Randomized Clinical Trials
Satoshi Hattori, Hajime Uno
Familial Cancer
|
January 31, 2018
Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers
Fay Kastrinos, Hajime Uno, Sapna Syngal
Contemporary Clinical Trials Communications
|
April 27, 2018
Decision on performing interim analysis for comparative clinical trials
Kyongsun Pak, Susanna Jacobus, Hajime Uno
Biostatistics (Oxford, England)
|
December 24, 2025
While-alive regression analysis of composite survival endpoints
Xi Fang, Hajime Uno, Fan Li
Statistics in Medicine
|
January 19, 2023
On assessing survival benefit of immunotherapy using long-term restricted mean survival time
Miki Horiguchi, Lu Tian, Hajime Uno
BMC Public Health
|
June 30, 2010
Clinical consequences of road traffic injuries among the elderly in Japan
Takashi Nagata, Hajime Uno, Melissa J Perry
Page
of 21